Tevogen Bio Holdings (TVGN) Cash & Equivalents (2021 - 2026)

Tevogen Bio Holdings has reported Cash & Equivalents for 6 years, with the latest figure at $692305.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 64.95% year-over-year to $692305.0; the trailing twelve-month figure through Mar 2026 stood at $692305.0 (down 64.95% YoY), and the FY2025 full-year result was $552372.0, down 56.95% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $692305.0, up from $552372.0 in the prior quarter.
• The five-year high for Cash & Equivalents was $5.7 million in Q1 2023, with the low at $143047.0 in Q3 2022.
• Historically, Cash & Equivalents has averaged $1.8 million across 5 years, with a median of $1.1 million in 2024.
• The largest YoY upside for Cash & Equivalents was 2350.54% in 2023 against a maximum downside of 80.81% in 2023.
• Tevogen Bio Holdings' Cash & Equivalents stood at $5.5 million in 2022, then tumbled by 80.81% to $1.1 million in 2023, then rose by 21.91% to $1.3 million in 2024, then plunged by 56.95% to $552372.0 in 2025, then grew by 25.33% to $692305.0 in 2026.
• The last three Cash & Equivalents figures came in at $692305.0 (Q1 2026), $552372.0 (Q4 2025), and $1.0 million (Q3 2025), per Business Quant data.